vs

Side-by-side financial comparison of Ardmore Shipping Corp (ASC) and Tarsus Pharmaceuticals, Inc. (TARS). Click either name above to swap in a different company.

Tarsus Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($151.7M vs $81.2M, roughly 1.9× Ardmore Shipping Corp). Ardmore Shipping Corp runs the higher net margin — 15.7% vs -5.5%, a 21.3% gap on every dollar of revenue. On growth, Tarsus Pharmaceuticals, Inc. posted the faster year-over-year revenue change (128.4% vs -15.5%). Over the past eight quarters, Tarsus Pharmaceuticals, Inc.'s revenue compounded faster (134.4% CAGR vs -6.0%).

Ardmore Shipping Corp is a global maritime transport company that owns and operates a fleet of mid-sized product and chemical tankers. It provides seaborne transport for petroleum products, specialty chemicals and bulk liquid commodities, serving energy, chemical and trading clients across key international trade routes.

Tarsus Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing innovative therapeutic candidates for unmet medical needs in ophthalmology, dermatology, and other specialty care areas. It operates primarily in the United States, with lead product candidates targeting common, underdiagnosed conditions including demodex blepharitis and rosacea.

ASC vs TARS — Head-to-Head

Bigger by revenue
TARS
TARS
1.9× larger
TARS
$151.7M
$81.2M
ASC
Growing faster (revenue YoY)
TARS
TARS
+143.9% gap
TARS
128.4%
-15.5%
ASC
Higher net margin
ASC
ASC
21.3% more per $
ASC
15.7%
-5.5%
TARS
Faster 2-yr revenue CAGR
TARS
TARS
Annualised
TARS
134.4%
-6.0%
ASC

Income Statement — Q3 FY2025 vs Q4 FY2025

Metric
ASC
ASC
TARS
TARS
Revenue
$81.2M
$151.7M
Net Profit
$12.8M
$-8.4M
Gross Margin
Operating Margin
16.1%
-5.3%
Net Margin
15.7%
-5.5%
Revenue YoY
-15.5%
128.4%
Net Profit YoY
-47.0%
63.8%
EPS (diluted)
$0.30
$-0.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ASC
ASC
TARS
TARS
Q4 25
$151.7M
Q3 25
$81.2M
$118.7M
Q2 25
$72.0M
$102.7M
Q1 25
$74.0M
$78.3M
Q4 24
$66.4M
Q3 24
$96.1M
$48.1M
Q2 24
$121.3M
$40.8M
Q1 24
$106.3M
$27.6M
Net Profit
ASC
ASC
TARS
TARS
Q4 25
$-8.4M
Q3 25
$12.8M
$-12.6M
Q2 25
$9.6M
$-20.3M
Q1 25
$6.3M
$-25.1M
Q4 24
$-23.1M
Q3 24
$24.1M
$-23.4M
Q2 24
$62.7M
$-33.3M
Q1 24
$39.2M
$-35.7M
Operating Margin
ASC
ASC
TARS
TARS
Q4 25
-5.3%
Q3 25
16.1%
-12.2%
Q2 25
13.5%
-21.6%
Q1 25
8.6%
-33.5%
Q4 24
-36.8%
Q3 24
25.4%
-52.3%
Q2 24
51.3%
-81.6%
Q1 24
37.2%
-136.5%
Net Margin
ASC
ASC
TARS
TARS
Q4 25
-5.5%
Q3 25
15.7%
-10.6%
Q2 25
13.3%
-19.8%
Q1 25
8.5%
-32.1%
Q4 24
-34.8%
Q3 24
25.1%
-48.7%
Q2 24
51.7%
-81.6%
Q1 24
36.9%
-129.4%
EPS (diluted)
ASC
ASC
TARS
TARS
Q4 25
$-0.17
Q3 25
$0.30
$-0.30
Q2 25
$0.22
$-0.48
Q1 25
$0.14
$-0.64
Q4 24
$-0.57
Q3 24
$0.55
$-0.61
Q2 24
$1.47
$-0.88
Q1 24
$0.92
$-1.01

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ASC
ASC
TARS
TARS
Cash + ST InvestmentsLiquidity on hand
$417.3M
Total DebtLower is stronger
$116.1M
$72.4M
Stockholders' EquityBook value
$628.2M
$343.4M
Total Assets
$799.8M
$562.2M
Debt / EquityLower = less leverage
0.18×
0.21×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ASC
ASC
TARS
TARS
Q4 25
$417.3M
Q3 25
$401.8M
Q2 25
$381.1M
Q1 25
$407.9M
Q4 24
$291.4M
Q3 24
$317.0M
Q2 24
$323.6M
Q1 24
$298.5M
Total Debt
ASC
ASC
TARS
TARS
Q4 25
$72.4M
Q3 25
$116.1M
$72.3M
Q2 25
$25.0M
$72.1M
Q1 25
$20.5M
$72.0M
Q4 24
$71.8M
Q3 24
$22.5M
$71.7M
Q2 24
$44.2M
$71.6M
Q1 24
$23.1M
$29.9M
Stockholders' Equity
ASC
ASC
TARS
TARS
Q4 25
$343.4M
Q3 25
$628.2M
$335.1M
Q2 25
$618.3M
$332.6M
Q1 25
$610.7M
$342.5M
Q4 24
$224.5M
Q3 24
$627.0M
$237.5M
Q2 24
$617.7M
$252.2M
Q1 24
$567.9M
$275.2M
Total Assets
ASC
ASC
TARS
TARS
Q4 25
$562.2M
Q3 25
$799.8M
$534.6M
Q2 25
$703.8M
$495.0M
Q1 25
$690.4M
$500.8M
Q4 24
$377.0M
Q3 24
$722.8M
$376.3M
Q2 24
$742.0M
$376.8M
Q1 24
$704.1M
$349.3M
Debt / Equity
ASC
ASC
TARS
TARS
Q4 25
0.21×
Q3 25
0.18×
0.22×
Q2 25
0.04×
0.22×
Q1 25
0.03×
0.21×
Q4 24
0.32×
Q3 24
0.04×
0.30×
Q2 24
0.07×
0.28×
Q1 24
0.04×
0.11×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ASC
ASC
TARS
TARS
Operating Cash FlowLast quarter
$17.9M
$19.3M
Free Cash FlowOCF − Capex
$13.0M
FCF MarginFCF / Revenue
8.6%
Capex IntensityCapex / Revenue
4.2%
Cash ConversionOCF / Net Profit
1.40×
TTM Free Cash FlowTrailing 4 quarters
$-22.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ASC
ASC
TARS
TARS
Q4 25
$19.3M
Q3 25
$17.9M
$18.3M
Q2 25
$11.2M
$-29.4M
Q1 25
$26.3M
$-20.7M
Q4 24
$-22.2M
Q3 24
$39.9M
$-8.7M
Q2 24
$48.4M
$-14.4M
Q1 24
$49.2M
$-37.8M
Free Cash Flow
ASC
ASC
TARS
TARS
Q4 25
$13.0M
Q3 25
$16.3M
Q2 25
$-30.4M
Q1 25
$-21.2M
Q4 24
$-22.3M
Q3 24
$-8.9M
Q2 24
$-15.4M
Q1 24
$-38.0M
FCF Margin
ASC
ASC
TARS
TARS
Q4 25
8.6%
Q3 25
13.8%
Q2 25
-29.6%
Q1 25
-27.1%
Q4 24
-33.5%
Q3 24
-18.6%
Q2 24
-37.8%
Q1 24
-137.5%
Capex Intensity
ASC
ASC
TARS
TARS
Q4 25
4.2%
Q3 25
1.6%
Q2 25
1.0%
Q1 25
0.8%
Q4 24
0.1%
Q3 24
0.6%
Q2 24
2.5%
Q1 24
0.6%
Cash Conversion
ASC
ASC
TARS
TARS
Q4 25
Q3 25
1.40×
Q2 25
1.17×
Q1 25
4.20×
Q4 24
Q3 24
1.65×
Q2 24
0.77×
Q1 24
1.25×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons